Extra treatment after lung cancer surgery for MRD-positive patients
Part of Cancer, Lungs & breathing clinical trials.
This study tests an additional treatment after surgery for stage II–III non-small cell lung cancer that may still have a chance of coming back (called MRD positive). It aims to see if this extra treatment reduces recurrence risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your lung cancer (non-small cell) is stage II or III and can be removed with surgery.
- You have never had immunotherapy (like PD-1 inhibitors) before.
- Your tumor does not have EGFR or ALK gene mutations.
- You are in good general health (active, good organ function) as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
This study tests an immunotherapy (PD-L1 inhibitor) for people with limited-stage small cell lung cancer whose cancer stayed stable after chemo and radiation but still has MRD (small traces of cancer in the blood). The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Hear when a new DFS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.